TY - JOUR
T1 - Potent and Prolonged Acting Cyclic Lactam Analogues of a-Melanotropin
T2 - Design Based on Molecular Dynamics
AU - Al-Obeidi, Fahad
AU - de L Castrucci, Ana M.
AU - Hadley, Mac E.
AU - Hruby, Victor J.
PY - 1989/12/1
Y1 - 1989/12/1
N2 - Utilizing results from previous structure-activity relationships and theoretical studies of a-melanotropin (a-MSH, Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) and its related superpotent analogues, Ac-[Nle4,D-Phe7]-α-MSH and Ac-[[formula omitted]]-α-MSH, we have designed a new class of a-MSH4_13and a-MSH4_10cyclic lactam fragment analogues of a-melanotropin. The cyclic peptides have the following general structures: Ac-[Nle4,[formula omitted],Glyn]-α-MSH4.13-NH2and Ac-[Nle4,[formula omitted],Yyy10]-α-MSH4.10-NH2, where = Glu or Asp and Yyy = Lys, Orn, Dab, or Dpr. Formation of the lactam bridge between the side-chain groups and Yyy was performed either in solution or on a solid-phase support. Seven cyclic peptides were prepared and bioassayed for their melanotropic potency by using standard frog (Rana pipiens) and lizard (Anolis carolinensis) skin bioassays. Relative to a-MSH (relative potency = 1), the potencies of the cyclic peptides in the lizard skin bioassay were as follows: a-MSH (1); Ac-[Nle4,Glu5,D-Phe7,Lys10,Gly11]-α-MSH4_13-NH2(6); Ac-[Nle4,Asp5j)-Phe7,Lys10,Gly11]-α-MSH4_13-NH2(100);Ac-[Nle4,Glu5,D-Phe7,Lys10]-α-MSH4_10-NH2(9);Ac-[Nle4,Asp5,D-Phe7,Lys10]-α-MSH4-10-NH2(90); Ac-[Nle4,Asp5,D-Phe7,Orn10]-α-MSH4_10-NH2(20); Ac-[Nle4,Asp6,D-Phe7,Dab10]-α-MSH4_10-NH2(5); Ac-r -i [Nle4,Asp5,D-Phe7,Dpr10]-α-MSH4_10-NH2(5). Similar results were obtained in the frog skin bioassay, but the analogues were much less potent. Cyclic melanotropins with 23-membered rings exhibited 100-fold higher melanotropic potency than a-MSH with selectivity for the lizard melanocyte receptors over the frog melanocyte receptors. Increasing or decreasing the ring size of these cyclic melanotropins from 23 diminishes the biological potency of the resulting cyclic peptide. The 23- and 24-membered ring analogues showed prolonged (residual) biological activities in both biological assays, but the smaller ring systems (20,21,22) did not. These results provide new insights into the structural and conformational requirements of a-MSH and its analogues at two different types of pigment cell (melanocyte) receptors.
AB - Utilizing results from previous structure-activity relationships and theoretical studies of a-melanotropin (a-MSH, Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) and its related superpotent analogues, Ac-[Nle4,D-Phe7]-α-MSH and Ac-[[formula omitted]]-α-MSH, we have designed a new class of a-MSH4_13and a-MSH4_10cyclic lactam fragment analogues of a-melanotropin. The cyclic peptides have the following general structures: Ac-[Nle4,[formula omitted],Glyn]-α-MSH4.13-NH2and Ac-[Nle4,[formula omitted],Yyy10]-α-MSH4.10-NH2, where = Glu or Asp and Yyy = Lys, Orn, Dab, or Dpr. Formation of the lactam bridge between the side-chain groups and Yyy was performed either in solution or on a solid-phase support. Seven cyclic peptides were prepared and bioassayed for their melanotropic potency by using standard frog (Rana pipiens) and lizard (Anolis carolinensis) skin bioassays. Relative to a-MSH (relative potency = 1), the potencies of the cyclic peptides in the lizard skin bioassay were as follows: a-MSH (1); Ac-[Nle4,Glu5,D-Phe7,Lys10,Gly11]-α-MSH4_13-NH2(6); Ac-[Nle4,Asp5j)-Phe7,Lys10,Gly11]-α-MSH4_13-NH2(100);Ac-[Nle4,Glu5,D-Phe7,Lys10]-α-MSH4_10-NH2(9);Ac-[Nle4,Asp5,D-Phe7,Lys10]-α-MSH4-10-NH2(90); Ac-[Nle4,Asp5,D-Phe7,Orn10]-α-MSH4_10-NH2(20); Ac-[Nle4,Asp6,D-Phe7,Dab10]-α-MSH4_10-NH2(5); Ac-r -i [Nle4,Asp5,D-Phe7,Dpr10]-α-MSH4_10-NH2(5). Similar results were obtained in the frog skin bioassay, but the analogues were much less potent. Cyclic melanotropins with 23-membered rings exhibited 100-fold higher melanotropic potency than a-MSH with selectivity for the lizard melanocyte receptors over the frog melanocyte receptors. Increasing or decreasing the ring size of these cyclic melanotropins from 23 diminishes the biological potency of the resulting cyclic peptide. The 23- and 24-membered ring analogues showed prolonged (residual) biological activities in both biological assays, but the smaller ring systems (20,21,22) did not. These results provide new insights into the structural and conformational requirements of a-MSH and its analogues at two different types of pigment cell (melanocyte) receptors.
UR - http://www.scopus.com/inward/record.url?scp=0024310869&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024310869&partnerID=8YFLogxK
U2 - 10.1021/jm00132a010
DO - 10.1021/jm00132a010
M3 - Article
C2 - 2555512
AN - SCOPUS:0024310869
SN - 0022-2623
VL - 32
SP - 2555
EP - 2561
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 12
ER -